Zobrazeno 1 - 2
of 2
pro vyhledávání: '"59"'
Autor:
David M. Ross, Jodi Braley, Timothy P. Hughes, Phuong Dang, Ilaria S. Pagani, Ivar O. Kommers, Verity A Saunders, Deborah L. White, Jarrad M. Goyne, Susan Branford, Mario Nicola, David T Yeung
Publikováno v:
Haematologica, 103(12), 2026-2032. Ferrata Storti Foundation
Pagani, I S, Dang, P, Kommers, I O, Goyne, J M, Nicola, M, Saunders, V A, Braley, J, White, D L, Yeung, D T, Branford, S, Hughes, T P & Ross, D M 2018, ' BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia ', Haematologica, vol. 103, no. 12, pp. 2026-2032 . https://doi.org/10.3324/haematol.2018.189787
Pagani, I S, Dang, P, Kommers, I O, Goyne, J M, Nicola, M, Saunders, V A, Braley, J, White, D L, Yeung, D T, Branford, S, Hughes, T P & Ross, D M 2018, ' BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia ', Haematologica, vol. 103, no. 12, pp. 2026-2032 . https://doi.org/10.3324/haematol.2018.189787
Accurate quantification of minimal residual disease during treatment of chronic myeloid leukaemia guides clinical decisions. The conventional minimal residual disease method, RQ-PCR for BCR-ABL1 mRNA, reflects a composite of the number of circulating
Autor:
Mauricette Michallet, Patrice Chevallier, Didier Blaise, Thierry Guillaume, Gérard Socié, Jacques Delaunay, Sabine Furst, Karin Bilger, Mohamad Mohty, Regis Peffault de la Tour, Noel Milpied, Stephane Vigouroux, Bruno Lioure, Philippe Moreau, Myriam Labopin, Jean El-Cheikh, Reza Tabrizi
Publikováno v:
Haematologica
Haematologica, Ferrata Storti Foundation, 2014, 99 (9), pp.1486-1491. ⟨10.3324/haematol.2014.108563⟩
Haematologica, 2014, 99 (9), pp.1486-1491. ⟨10.3324/haematol.2014.108563⟩
Haematologica, Ferrata Storti Foundation, 2014, 99 (9), pp.1486-1491. ⟨10.3324/haematol.2014.108563⟩
Haematologica, 2014, 99 (9), pp.1486-1491. ⟨10.3324/haematol.2014.108563⟩
We prospectively evaluated the safety and efficacy of a clofarabine, intravenous busulfan and antithymocyte globulin-based reduced-toxicity conditioning (CloB2A2) regimen before allogeneic stem cell transplantation. Thirty high-risk patients (median